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Wong MS, Delansorne R, Man RYK, Svenningsen P, Van-
houtte PM. Chronic treatment with vitamin D lowers arterial blood
pressure and reduces endothelium-dependent contractions in the aorta
of the spontaneously hypertensive rat. Am J Physiol Heart Circ
Physiol 299: H1226–H1234, 2010. First published August 6, 2010;
doi:10.1152/ajpheart.00288.2010.—Vitamin D has cardiovascular
protective effects besides regulating calcium homeostasis. To examine
the chronic in vivo effect of a physiological dose of 1,25-dihydroxyvi-
tamin D3 on the occurrence of endothelium-dependent contractions,
spontaneously hypertensive rats (SHR) and Wistar-Kyoto rats (WKY)
were treated with the vitamin D derivative for 6 wk. The serum
1,25-dihydroxyvitamin D3 level of both treated WKY and SHR was
significantly higher than in untreated rats while the mean arterial
blood pressure of the treated SHR was significantly lower than that of
control SHR. Aortic rings with or without endothelium were studied
in conventional organ chambers for isometric force measurement.
Confocal microscopy was used to measure the cytosolic free calcium
concentration (with the fluorescent dye fluo 4) and reactive oxygen
species (ROS; with dichlorodihydrofluorescein diacetate). Reverse
transcription PCR and Western blotting were used to determine the
mRNA and protein expression level of cyclooxygenase-1 (COX-1),
prostacyclin synthase, and thromboxane synthase. The endothelium-
dependent concentration-contraction curves to both acetylcholine- and
A-23187-induced contractions were shifted to the right in aortas from
treated SHR but not from treated WKY. The chronic treatment
normalized the relaxations of contracted preparations to acetylcholine.
There were no significant differences in the increases in cytosolic free
calcium concentration evoked by acetylcholine and A-23187 between
control and treated groups. The endothelial ROS level was higher in
SHR than WKY aortas and reduced by the chronic treatment. The
gene and protein expression studies indicated that the overexpression
of COX-1 observed in SHR aorta was reduced by the chronic
treatment. These results demonstrate that chronic treatment with
1,25-dihydroxyvitamin D3 modulates vascular tone and this modula-
tion is accompanied by a lowered blood pressure, reduced expression
of COX-1 mRNA and protein, and reduced ROS level in SHR. The
reduction in endothelium-dependent contractions does not involve the
surge in endothelial cytosolic calcium concentration that initiates the con-
tractions.
1,25-dihydroxyvitamin D3; endothelium-derived contracting factors;
cyclooxgenase-1; reactive oxygen species
VITAMIN D DEFICIENCY OCCURS in 30–50% of the population (24),
and it can lead to various cardiovascular disorders (12, 17, 32).
The serum concentration of 1,25-dihydroxyvitamin D3, the
most active metabolite of vitamin D, is inversely related to
arterial blood pressure (22), and people with suboptimal pro-
duction and/or intake of vitamin D have a higher risk of
hypertension (7, 18, 38). In rats, vitamin D deficiency has been
linked to cardiac fibrosis and hypertrophy (56, 57).
The endothelium modulates vascular tone by releasing va-
sodilator substances to control the underlying smooth muscle
cells (53). Among these substances, nitric oxide (NO), pro-
duced by endothelial NO synthase (eNOS), plays a major role
as endothelium-derived relaxing factor (EDRF) (8, 30, 53).
When the production of NO by eNOS is reduced, with ageing
or in the course of diseases such as diabetes, endothelial
dysfunction ensues (53). In that regard, 1,25-dihydroxyvitamin
D3 has favorable effects on endothelial cells by protecting them
against the deleterious effects of glycation end products and
increasing the activity of eNOS (44). In addition to the release
of NO, under certain circumstances, in particular when the NO
production is reduced, the endothelial cells release vasocon-
strictor prostanoids that elicit endothelium-dependent contrac-
tions (8, 51, 53, 54). In particular, in the aorta of the sponta-
neously hypertensive rat (SHR), such endothelium-dependent
contractions are caused mainly by endothelium-derived en-
doperoxides and prostacyclin, which activate thromboxane-
prostanoid (TP) receptors of the vascular smooth muscle cells
(10, 13, 27, 46, 51, 52, 61). The unbalanced augmented
production of endothelium-derived contraction factor (EDCF)
is a characteristic of endothelial dysfunction (53–55), and such
imbalance has been observed in blood vessels of humans [with
atherosclerosis, myocardial infarction, and hypertension (3, 43,
53, 55)] and in animals [including the adult SHR (26), aging
normotensive animals (21, 59), and diabetic rats (39)]. Previ-
ous in vitro studies of the laboratory showed that supraphysi-
ological concentrations of 1,25-dihydroxyvitamin D3 acutely
reduce endothelium-dependent contractions in the SHR aorta
(58). This pharmacological observation prompted the present
experiments, which were designed to determine whether or not
chronic in vivo treatment with a physiological dose of 1,25-
dihydroxyvitamin D3 affects endothelium-dependent contrac-
tions in the rat aorta.
METHODS
Animals and tissue preparation. Adult SHR and Wistar-Kyoto
(WKY) rats (36 wk old) were anesthetized (pentobarbital sodium, 30
mg·ml1 ·kg1, ip injection), and mini-osmotic pumps (model 2006;
Alzet, Cupertino, CA) were implanted subcutaneously. In the treat-
ment group, the pumps were loaded with 1,25-dihydroxyvitamin D3,
Address for reprint requests and other correspondence: P. M. Vanhoutte,
Dept. of Pharmacology, Univ. of Hong Kong, 2/F, Laboratory Block, Li Ka
Shing Faculty of Medicine, Faculty of Medicine Bldg., 21 Sassoon Rd.,
Pokfulam, Hong Kong (e-mail: vanhoutt@hkucc.hku.hk).
Am J Physiol Heart Circ Physiol 299: H1226–H1234, 2010.
First published August 6, 2010; doi:10.1152/ajpheart.00288.2010.
0363-6135/10 Copyright © 2010 the American Physiological Society http://www.ajpheart.orgH1226
 by 10.220.33.4 on January 15, 2017
http://ajpheart.physiology.org/
D
ow
nloaded from
 
dissolved in propylene glycol, which diffused out at a rate of 10
ng·100 g body wt1 ·day1 (60). In the control group, they were filled
with propylene glycol alone. The rats were returned to their cages
after recovery from anesthesia and were housed in a room with
standardized temperature (21  1°C) and exposed to a 12:12-h
dark-light cycle. They had free access to standardized diet (LabDiet
5053, Philadelphia, PA) and tap water. After 6 wk, the rats were
anesthetized again, and their arterial blood pressure was measured by
means of a polyethylene cannula inserted in the left carotid artery and
connected to a pressure transducer (P23 1D; Gould Statham, Oxnard,
CA). Next, the animals were killed, and their blood was collected for
the determination of the serum level of 1,25-dihydroxyvitamin D3.
The thoracic aorta was isolated and placed immediately in cold
Krebs-Ringer buffer with the following composition (in mM): 118
NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, and
11.1 glucose (control solution). The adhering fat and connective tissue
were removed. The aortas were cut into rings (length 3 mm). In
some rings, the endothelium was removed mechanically by gently
rubbing the intimal surface of the rings with a syringe needle. The
endothelial layer of some rings was collected for reverse transcription
PCR analysis and Western blotting. The other rings were used to
measure isometric force or the changes in either cytosolic free calcium
or reactive oxygen species (ROS) in the endothelial cells. This
investigation was approved by the Committee on the Use of Labora-
tory Animals for Teaching and Research of the University of Hong
Kong.
1,25-Dihydroxyvitamin D3 radioimmunoassay. 1,25-Dihy-
droxyvitamin D3 was purified from serum by monoclonal immu-
noextraction and quantified using a 125I radioimmunoassay accord-
ing to the manufacturer’s instructions (Immunodiagnostic Systems,
Fountain Hills, AZ).
Isometric force. The rings were suspended in organ chambers that
contained 5 ml of control solution (37°C) aerated with a 95% O2-5%
CO2 gas mixture (pH 7.4). Each ring was connected to a force
transducer (model MLT0201/D; AD Instruments, Colorado Spring,
CO) for isometric force recording. The rings were stretched to an
optimal tension of 2.5 g (determined in preliminary experiments; data
not shown) and allowed to equilibrate for 90 min. They were then
exposed to 60 mM KCl to obtain a submaximal contraction. All
further contractions were expressed in percentage of this reference
response. Some rings with endothelium were incubated with N-nitro-
L-arginine methyl ester (L-NAME; 104 M) for 30 min to optimize
endothelium-dependent contractions (1). They were then exposed to
cumulative concentrations of acetylcholine (108 to 105 M) or of the
calcium ionophore A-23187 (108 to 3  106 M). Rings without
endothelium were exposed to increasing doses of 15(S)-hydroxy-11,9-
(epoxymethano)prostadienoic acid (U-46619, thromboxane mimetic,
1010 to 106 M) to obtain endothelium-independent contractions. To
obtain endothelium-dependent relaxations, some rings with endothe-
lium were first contracted with phenylephrine (106 M) and then
exposed to increasing concentration of acetylcholine (1010 to 103
M). Relaxations were expressed in percentage of phenylephrine-
induced contractions.
Cytosolic free calcium and ROS levels. Cytosolic free calcium
change was monitored and measured by confocal microscopy after
incubation with fluo 4-AM [2  105 M (29, 48, 58)]. ROS were
labeled with dichlorodihydrofluorescein diacetate (DCF; 4  105
M). The dyes were dissolved in 0.1% (vol/vol) dimethyl sulfoxide
(DMSO) first followed by dilution with control solution containing
0.02% (vol/vol) pluronic acid F-127. Aortic rings for calcium mea-
surement were incubated in the dye mixture for 1 h, whereas those for
ROS measurement were incubated for 10 min to allow penetration of
the dyes in the tissue and cleavage of acetyloxymethyl ester. After
incubation, the rings were cut longitudinally into strips and fixed into
a transparent chamber with the intimal side faced downward, leaving
a 1-mm gap between the endothelium and the cover slip. The whole
system was connected to a peristaltic pump for continuous perfusion
with oxygenated control solution (95% O2-5% CO2) loaded with
different drugs. The incoming solution was maintained at 37°C, and
the perfusion rate was 2 ml/min. The tissues were first superfused with
control solution for 10 min to wash away excess dye. For calcium
measurements, three different concentrations (selected from the con-
centration-contraction curves obtained in the organ chambers) of
either acetylcholine (107, 106, and 105 M) or A-23187 (107, 3
107, and 106 M) were added. Real-time changes in cytosolic free
calcium concentration in the endothelial cells were monitored using a
laser confocal microscope at 1-s intervals for 300 s. For ROS mea-
surements, single still images were taken to quantify the basal ROS
level since time series scanning by the laser confocal may lead to
intense background fluorescence. The maximal change in fluorescence
intensity was calculated (expressed as percent increase over the basal
fluorescence intensity) and compared between the control and treated
groups. To mimic the organ chamber experiments, all strips were
incubated with L-NAME for 30 min before the addition of either
acetylcholine or A-23187.
The microscope used in this study was an inverted Nikon Eclipse
TE300 with 10 objective. It was attached to a confocal argon ion
Radiance-2100 laser scanning unit (Bio-Rad, Hertfordshire, UK). An
Table 1. Sequences of PCR primer pairs and anticipated size of the amplified products for the genes of COX-1, prostacyclin
synthase, thromboxane synthase, and -actin
Gene Name Sense Antisense Size, bp
COX-1 5=-GGGAAACTTAAGTACCAGGTG 5=-CATCTGCTTTTCGGGCGGGAC 108
Prostacyclin synthase 5=-TCTGCAGCTTCCAAATTTCAA 5=-CTGCCTCCTTCTGTGGAGTCA 144
Thromboxane synthase 5=-GGGGCTTCTCAAGTTCGAAGT 5=-CCCAACTTCCTCAGTCTTGAG 117
-Actin 5=-CGAGTCCGCGTCCACCCGCGA 5=-GACGACGAGCGCAGCGATATC 106
COX-1, cyclooxygenase-1.
Table 2. Mean arterial blood pressure and serum 1,25-dihydroxyvitamin D3 levels of treated [1,25-dihydroxyvitamin D3 (10
ng·100 g body wt1 ·day1)] and untreated (control) SHR and WKY
Strain
Arterial Mean Blood Pressure, mmHg Serum 1,25-Dihydroxyvitamin D3, pg/ml
Control Treated Control Treated
WKY 130.5 7.2 128.8 6.8 23.8 2.3 48.4 9.8*
SHR 198.3  5.4 165.6 12.8* 20.9 1.3 54.9 11.6*
Data are shown as means SE; n 6 rats in each group. WKY, Wistar-Kyoto rats; SHR, spontaneously hypertensive rats. *Statistically significant differences
with the controls (P  0.05).
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argon ion laser line (488 nm) was directed to the sample to excite the
fluorescent probes. The emitted fluorescence was detected via a band
pass filter (510–525 nm). An image field of 256  256 pixels was
selected randomly on the aortic segment. The resulting fluorescence
was a mean of all pixels in this chosen field. The LaserSharp 2000
program (Bio-Rad, Hercules, CA) was used to record the real time
changes in mean intensity of the images. The parameters of the
confocal laser scanning were kept constant, for all experiments, as
follows: 1) zoom factor  4; 2) iris  1.2; 3) gain  98; and 4) inten-
sity  36.4.
RNA extraction. The aorta was cut open with the endothelial cell
layer facing upward. The endothelial cells were collected by scraping
with a spatula (Cell Lifter; Corning Costar, New York, NY) and were
pooled in 1 ml of Tri Reagent (Molecular Research Center, Cincin-
nati, OH). To improve the efficiency of RNA isolation, cells were
triturated by thrusting the Tri Reagent cell mixture up and down a
syringe needle to facilitate cell rupture. Total RNA was isolated with
Tri Reagent according to the manufacturer’s instructions.
Real-time PCR. Total RNA (500 ng) was used for reverse tran-
scription. The total reverse transcription product (1 	l) was added to
the PCR reaction mixture (20 	l) containing 10 	l 2 SYBR Green
PCR master mix (Applied Biosystems) and the primers (sense and
antisense; 1 	M) for PCR. The real-time PCR reactions were moni-
tored using the 7900HT Fast Real-Time PCR System (Applied Bio-
systems, Foster City, CA). The primer sequences are listed in Table 1.
Standard reference curves were obtained concomitantly with the
unknown samples for the calculation of gene copy numbers in each
real-time PCR experiment. Gene expressions were normalized to that
of -actin.
Protein extraction and immunoblotting. The aorta was cut open,
and the endothelial cells were collected by scraping with a spatula
(Cell Lifter; Corning Costar) and pooled into lysis buffer (20 mmol/l
Tris ·HCl, 1% Triton X-100, 150 mmol/l NaCl, 1 mmol/l EDTA, 1
mmol/l EGTA, 2.5 mmol/l sodium pyrophosphate, 1 mmol/l -glyc-
erophosphate, and 1 mmol/l sodium orthovanadate) supplemented
with a cocktail of protease inhibitors (100 mmol/l phenylmethylsul-
fonyl fluoride, 10 	g/ml trypsin inhibitor, 1 mg/ml leupeptin, and 2
	g/ml pepstatin A). The mixture was centrifuged at 5,000 rpm at 4°C
for 3 min, and the supernatant was kept at 80°C until use. For gel
electrophoresis, 20 	g of tissue homogenate protein were used. The
samples were mixed with 1 sample buffer (NuPAGE LDS Sample
Buffer 4; Invitrogen, Carlsbad, CA) and 1 reducing agent (10
Reducing Agent; Invitrogen) and diluted with ultrapure water to
obtain 40 	l. The samples were boiled for 10 min at 95°C and
subsequently separated by SDS-PAGE (10%) at 200 V, 500 mA for 1
h. The proteins were transferred electrophoretically onto nitrocellu-
lose membranes. The blotting was performed at 1,000 V, 300 mA for
2 h. Subsequently, the membranes were blocked in Tris-buffered
saline with 5% dry milk at room temperature for 2 h, washed in
Tris-buffered saline Tween 20 (TBST), and then incubated with
primary antibodies (1:200) overnight at 4°C. Next, the membranes
were incubated with either horseradish peroxidase-conjugated anti-
rabbit antibody for thromboxane synthase or anti-mouse antibody
(1:3,000 in milk, room temperature, for 2 h; Amersham Biosciences,
Piscataway, NJ) for cyclooxygenase (COX)-1 and prostacyclin syn-
thase. Bound secondary antibody was detected by chemiluminescence
(Amersham Biosciences) and exposed to X-ray film. To reprobe
-actin, membranes were washed with Tris-Tween buffered saline
and incubated with the monoclonal -actin antibody (Sigma, St.
Louis, MO). The optical densities of the protein bands were deter-
mined with a computerized program (MultiAnalysis; Bio-Rad Labo-
ratories, Irvine, CA). Densitometric analysis was normalized to the
immunoreactive -actin band.
Data analysis. Results are presented as means  SE with n
referring to the number of rats used. Statistical analysis was performed
using Student’s t-test for comparison of two groups or two-way
ANOVA followed by the Bonferroni post hoc test for unpaired
observations. All statistical comparisons were performed using Prism
version 3a (GraphPad Software, San Diego, CA). Differences were
considered to be statistically significant when P was 0.05.
Chemicals. Acetylcholine, A-23187, DCF, L-NAME, pluronic acid
F-127, and 1,25-dihydroxyvitamin D3 were purchased from Sigma
Chemical. U-46619 was purchased from Biomol (St. Louis, MO).
Dimethyl sulfoxide (DMSO) was purchased from Merck (Darmstadt,
Germany). EIA kits were purchased from Cayman Chemical (Ann
Arbor, MI). Fluo 4-AM was purchased from Molecular Probes (Eu-
gene, OR). All drugs, except U-46619 and the calcium ionophore
A-23187, were prepared daily by dissolving in absolute DMSO (0.1%
in the organ bath) and further diluted with control solution.
Fig. 1. Contractions to cumulative concentrations of U-46619 in rings of spontaneously hypertensive rats (SHR, left) and Wistar-Kyoto rats (WKY, right) aortas
without endothelium taken from control rats or rats chronically treated with 1,25-dihydroxyvitamin D3 (10 ng 100 g body wt1 day1). Data are expressed as
a percentage of the reference contraction to 60 mM KCl and shown as means  SE (n  6).
H1228 1,25-DIHYDROXYVITAMIN D3 AND EDCF
AJP-Heart Circ Physiol • VOL 299 • OCTOBER 2010 • www.ajpheart.org
 by 10.220.33.4 on January 15, 2017
http://ajpheart.physiology.org/
D
ow
nloaded from
 
RESULTS
Blood pressure. The mean arterial blood pressure of
untreated SHR was significantly higher than that of WKY
(Table 2). The mean arterial blood pressure was signifi-
cantly lower in treated SHR compared with untreated rats of
the same strain, whereas no significant changes were ob-
served in WKY (Table 2).
Serum 1,25-dihydroxyvitamin D3. The serum level of 1,25-
dihydroxyvitamin D3 was significantly higher in the treated
rats compared with their respective controls. There were no
significant differences between SHR and WKY (Table 2).
Isometric force measurements. In rings without endothe-
lium, U-46619 evoked comparable concentration-dependent
contractions in aortas of both SHR and WKY (Fig. 1). No
significant difference was found between control and treated
rats of either strain.
In aortic rings with endothelium, acetylcholine and A-23187
evoked concentration-dependent, endothelium-dependent con-
tractions. The responses were significantly greater in prepara-
tions from SHR than in those from WKY. Both acetylcholine-
and the A-23187-induced contractions were inhibited signifi-
cantly in aortas from the treated SHR group compared with the
SHR controls. There was no significant difference in contrac-
tions to either acetylcholine or A-23187 between aortas from
control and treated WKY (Fig. 2).
In phenylephrine (106 M)-contracted SHR rings with en-
dothelium, acetylcholine (1010 to 103 M) evoked concen-
tration-dependent, triphasic responses (relaxation-contraction-
relaxation). The secondary contraction starting at 106 M was
absent in aortas of the treated SHR group (Fig. 3).
Cytosolic free calcium. Both acetylcholine (107, 106, and
105 M) and A-23187 (107, 3  107, and 106 M) caused
Fig. 2. Contractions to cumulative concentrations of acetylcholine (left) or A-23187 (right) in rings of SHR (top) or WKY (bottom) aortas with endothelium taken
from control rats or rats chronically treated with 1,25-dihydroxyvitamin D3 (10 ng ·100 g body wt1 · day1). Data are expressed as a percentage of the reference
contraction to 60 mM KCl and shown as means  SE (n  6). *Statistically significant differences with controls (P  0.05).
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concentration-dependent increases in cytosolic free calcium
concentration in aortas of both SHR and WKY. The increases
in calcium concentration caused by 106 and 105 M acetyl-
choline were significantly higher in SHR compared with WKY
aortas. Chronic treatment with 1,25-dihydroxyvitamin D3 did
not significantly affect these increases in calcium concentration
in either strain (Fig. 4).
ROS level. The ROS level was significantly higher in the
endothelial cells of SHR than in those of WKY. Chronic
treatment of 1,25-dihydroxyvitamin D3 significantly reduced
the endothelial ROS level in the SHR but not in WKY aortas
(Fig. 5).
Gene and protein expressions. Real-time PCR (Fig. 6) and
Western blotting (Fig. 7) revealed a significant decrease in the
mRNA and protein expression of COX-1 in endothelial cells of
SHR treated with 1,25-dihydroxyvitamin D3 compared with
control SHR, whereas it was comparable in treated and control
WKY. No differences in gene and protein expression were
observed for prostacyclin and thromboxane synthases after
chronic vitamin D treatment in either SHR or WKY.
DISCUSSION
The present experiments were designed to determine
whether or not chronic in vivo treatment with a physiological
dose of 1,25-dihydroxyvitamin D3 affects endothelium-depen-
dent contractions.
The levels of mRNA and protein of COX-1 are comparable
in the aorta of 5- and 10-wk-old WKY and SHR (33), but these
levels are significantly higher in preparations of 36 (10)- or 40
(33)-wk-old (33) SHR than in those of age-matched WKY.
Because overexpression of COX-1 is the major factor that
contributes to the overproduction of EDCF in the SHR (47),
the present experiments were performed on aortas of 36-wk-
old rats. The rat aorta is a standard preparation to measure
Fig. 3. Relaxation to cumulative concentrations of acetylcholine in phenyleph-
rine-contracted rings of SHR aorta with endothelium taken from control rats or
rats chronically treated with 1,25-dihydroxyvitamin D3 (10 ng ·100 g body
wt1 · day1). Data are expressed as a percentage of the contraction to
phenylephrine (106 M) and shown as means  SE (n  5). *Statistically
significant differences with controls (P  0.05).
Fig. 4. Bar graphs showing increases in fluores-
cence intensity (representing the cytosolic free cal-
cium concentration) in response to three concentra-
tions of either acetylcholine (ACh; top) or A-23187
(bottom) as a percentage of the basal calcium level
in aortic endothelial cells from control and 1,25-
dihydroxyvitamin D3-treated (10 ng ·100 g body
wt1 · day1) WKY and SHR. Data are expressed
as means  SE (n  5). *Statistically significant
differences between WKY and SHR. NS, not sig-
nificantly different.
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EDCF-mediated responses (1, 14, 26, 47) and allows the
measure of the change in cytosolic free calcium and ROS
levels (48, 58).
The in vivo treatment with 1,25-dihydroxyvitamin D3 did
not affect ex vivo contractions evoked by the TP receptor
agonist U-46619 in SHR preparations without endothelium but
reduced the contractions to both acetylcholine and the calcium
ionophore A-23187 in those with endothelium. These obser-
vations demonstrate that the chronic intake of vitamin D
reduces endothelium-dependent contractions without affecting
the responsiveness of the vascular smooth muscle of the SHR
aorta.
An increase in cytosolic calcium concentration in the endo-
thelial cells is the first step in the process leading to EDCF-
mediated responses (48, 58). The calcium-triggering effect of
acetylcholine is receptor-mediated, whereas the calcium iono-
phore A-23187 causes the cells to release potassium rapidly in
exchange for an uptake of calcium (36). Thus the observations
that the aortas of treated SHR exhibit a reduced endothelium-
dependent response to both the muscarinic agonist and the
calcium ionophore suggest that 1,25-dihydroxyvitamin D3 acts
downstream of the surge in calcium concentration. This inter-
pretation was confirmed by measuring changes in calcium
fluorescence in the endothelial cells exposed to acetylcholine
and A-23187. Indeed, both agonists evoked concentration-
dependent increases in cytosolic calcium concentration, and
these increments were not affected by the chronic treatment
with vitamin D. This contrasts with the previous findings that
acute exposure to a supraphysiological concentration of 1,25-
dihydroxyvitamin D3 reduces the increase of calcium in the
endothelial cells in response to acetylcholine but not to
A-23187. The present findings confirm that acetylcholine, but
not A-23187, causes larger increases in endothelial calcium
concentration in the SHR than in the WKY aorta (48). They
demonstrate that the increase in calcium concentration evoked
by both agonists is not affected by the chronic treatment with
Fig. 5. Levels of reactive oxygen species (ROS) in aortic endothelial cells of
control and 1,25-dihydroxyvitamin D3 (10 ng ·100 g body wt1 · day1)-
treated SHR and WKY. Data are expressed as means  SE (n  5).
*Statistically significant difference with controls (P  0.05). #Statistically
significant differences between SHR and WKY aortas (P  0.05).
Fig. 6. Real-time PCR results showing the gene expression levels of cycloox-
ygenase-1 (COX-1), prostacyclin synthase (PGIS), and thromboxane synthase
(TBXS) in aortic endothelial cells in control (C) or 1,25-dihydroxyvitamin D3
(10 ng ·100 g body wt1 · day1)-treated (T) SHR and WKY. Data are
expressed as means  SE (n  6). *Statistically significant difference with
controls (P  0.05). #Statistically significant differences between SHR and
WKY aortas (P  0.05).
Fig. 7. A: Western blot showing the protein expression of COX-1, PGIS, and
TBXS in endothelial cells. B: the protein expressions of these enzymes relative
to -actin are expressed as a bar graph. Data are expressed as means  SE
(n  6). *Statistically significant difference with controls (P  0.05). #Sta-
tistically significant differences between SHR and WKY aortas (P  0.05).
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vitamin D and thus that the latter does not interfere with the
surge in calcium required to initiate endothelium-dependent
contractions.
The triphasic (relaxation-contraction-relaxation) response to
acetylcholine demonstrated in the present study is in line with
previous observations in the same preparation (26, 45). The
secondary contraction phase illustrates the EDCF-mediated
component since it can be prevented by the cyclooxygenase
inhibitor indomethacin (26, 42). The present study demon-
strates that the secondary contraction was absent in the aortas
of treated SHR, which further confirms that chronic treatment
with 1,25-dihydroxyvitamin D3 prevents the occurrence of
endothelium-dependent contractions, and thus the endothelial
dysfunction of this animal model of essential hypertension.
The lack of effect of the chronic treatment on the first relaxing
phase shows that it has minimal effects on the NO-dependent
pathway. Earlier bioassay studies have demonstrated that the
release of EDRF/NO is normal in aortas of SHR treated with
indomethacin (25).
Acetylcholine- and A-23187-induced endothelium-depen-
dent contractions were reduced by the chronic treatment with
vitamin D in the SHR but not in their normotensive counterpart
WKY. These results indicate that the chronic action of vitamin
D is specifically targeting the disease model. When considering
the differences between SHR and WKY, the major enzymes
downstream of the initial calcium surge, which are involved in
the generation of EDCF, were studied (49, 51, 53). They
included COX-1, prostacyclin synthase, and thromboxane syn-
thase. The expression levels of COX-1 and prostacyclin syn-
thase were augmented in the aortas of untreated SHR compared
with those of WKY, which confirms results from previous
studies and explains the overproduction of EDCF in the SHR
aorta (10, 11, 33, 49). Both the mRNA expression and protein
presence of COX-1 was reduced in the treated SHR, but no
such reduction was observed in preparations from WKY de-
spite similar increases in the plasma level of vitamin D3,
demonstrating that 1,25-dihydroxyvitamin D3 chronically pre-
vents the overexpression of COX-1, hence reducing the over-
production of EDCF in the disease model without altering the
constitutive expression of the enzyme in the normotensive
animals. 1,25-Dihydroxyvitamin D3 downregulates the mRNA
expression of COX-2 in human neonatal monocytes (34) and
prostate cancer cells (31). COX-1 and COX-2 are the two
major isoforms of cyclooxygenase, and both are heme proteins
with comparable ability in transforming arachidonic acid into
endoperoxides (9, 50), the precursor of vasoconstrictor prosta-
noids that, per se, can act as EDCF (10). Selective COX-1
inhibitors abolish endothelium-dependent contractions of the
SHR aorta, whereas preferential COX-2 inhibitors only mod-
estly reduce the response (10, 62). In addition, endothelium-
dependent contractions can be induced in aortas of COX-2
knockout but not of COX-1 knockout mice (47). Taken in
conjunction, those previous findings demonstrate that COX-1
is responsible for the production of EDCF in rodents (51, 54).
The present data suggest that the ex vivo inhibition of endo-
thelium-dependent contractions afforded by the chronic in vivo
treatment with 1,25-dihydroxyvitamin D3 may well be because of
a direct effect of the vitamin preventing the overexpression of the
COX-1 gene and the resulting increased protein presence of the
enzyme, which is the major source of EDCF.
The present study demonstrates a reduction of the basal ROS
level in the endothelial cells of SHR treated chronically with
1,25-dihydroxyvitamin D3, which may explain the normaliza-
tion of the COX-1 expression in the hypertensive animals.
Oxidative stress contributes to the upregulation of cyclooxy-
genases (4, 19). In arteries of rats with streptozotocin-induced
diabetes, both COX-1 and COX-2 are upregulated, and this can
be prevented by antioxidant treatment (40). Vitamin D pos-
sesses antioxidant activities and protects cells from oxidative
stress (5, 16, 41). Besides vitamin D, several antioxidants
reduce arterial blood pressure in various hypertensive models
(2, 6, 20, 63).
In male Sprague-Dawley rats, the normal serum vitamin D
concentration decreases with aging and is around 58 pg/ml in
12-mo-old rats (60). The serum vitamin D level of normal
WKY in the present study is 24 pg/ml, which appears to be
relatively low. This may be because of the different strain of
the rat used, different composition of the diet, or different
housing conditions. The vitamin D level in both strains in-
creased after treatment but remained within the physiological
range (15, 60). Although the serum level of 1,25-dihydroxyvi-
tamin D3 was comparable in the treated groups of both the
normotensive and hypertensive rats, only the treated SHR
showed a substantial decrease in arterial blood pressure, sug-
gesting that the chronic administration of vitamin D interferes
with the disease process without affecting the cardiovascular
system under normal conditions. Vitamin D lowers blood
pressure in hypertensive patients (35). The underlying mecha-
nisms include suppression of the renin-angiotensin-aldosterone
system (23), parathyroid hormone secretion (37), and improve-
ment of endothelial function in vascular cells (28, 64). Earlier
work suggests that the overexpression of COX-1 in the aorta of
the SHR follows rather than precedes the increase in arterial
blood pressure (11, 33). Therefore, it is possible that the
reduction in COX-1 expression and/or the endothelium-depen-
dent contractions caused by the chronic treatment of vitamin D
observed in the present study may be secondary to the reduced
arterial blood pressure in the treated SHR.
In conclusion, chronic treatment of 1,25-dihydroxyvitamin
D3 reduces endothelium-dependent contractions in the SHR
aorta. The inhibitory effect is accompanied by a lowered blood
pressure, reduction in the basal endothelial ROS level, and
downregulation of COX-1 expression. These changes are not
seen in normotensive animals.
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